Investigating new treatments for triple-negative breast cancer
Official title: Mechanistic studies of hirsutinolides and azetidine-based small molecule inhibitors of STAT3
Funded at Cedars-Sinai Medical Center · NIH-11061191 · Data updated 2026-11-12
This study is exploring new ways to treat triple-negative breast cancer by targeting how the cancer cells use sugar and handle stress, with the hope of finding better treatment options that could help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $686,846 |
| NIH project number | 5R01CA283313-02 |
| Project ID | NIH-11061191 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have limited treatment options.
✕Less likely to help
Patients with other types of breast cancer or those who have already responded well to existing treatments may not benefit from this research.
What this research studies
This research focuses on developing new therapeutic strategies for triple-negative breast cancer (TNBC), a type of cancer that often does not respond well to standard chemotherapy. The approach involves targeting specific cellular mechanisms that TNBC cells rely on for survival, particularly those related to glucose metabolism and oxidative stress. By using small molecule inhibitors that affect these pathways, the research aims to induce cell death in cancer cells and inhibit tumor growth. Patients may benefit from potential new treatment options that could improve outcomes for this challenging cancer type.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple-negative breast cancer.
How similar studies have gone: Other research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach may lead to significant advancements.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Turkson, James K — Cedars-Sinai Medical Center
- Study coordinator: Turkson, James K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.